Abstract | AIM: STUDY SELECTION CRITERIA: Randomized controlled trials comparing budesonide to corticosteroids, 5-ASA products or placebo were included. Trials had to report on the effectiveness of treatment (defined as decreasing or maintaining Crohn's Disease Activity Index, CDAI, scores < or = 150) or adverse events. DATA ANALYSIS: After assessing the validity of study design and independent, duplicate data extraction from selected trials, summary relative risks (RR) were calculated for each outcome. A test of heterogeneity was also calculated for each outcome using a random effects model. RESULTS:
Budesonide was more likely to induce remission than placebo (RR=1.82, 95% CI: 1.15-2.88) or 5-ASA (RR=1.73, 95% CI: 1.26-2.39), although only one trial compared budesonide to 5-ASA products. Although budesonide induced remission less frequently than conventional corticosteroids (RR=0.87, 95% CI: 0.76-0.995), there was no significant difference between conventional corticosteroids and budesonide for inducing remission among patients with a low disease activity (initial CDAI=200-300). Budesonide was significantly less likely to cause corticosteroid-associated adverse events than conventional corticosteroids (RR=0.65, 95% CI: 0.53-0.80). No significant difference in total adverse events or corticosteroid-associated adverse events was demonstrated between budesonide and 5-ASA or placebo. CONCLUSION:
|
Authors | S V Kane, P Schoenfeld, W J Sandborn, W Tremaine, T Hofer, B G Feagan |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 16
Issue 8
Pg. 1509-17
(Aug 2002)
ISSN: 0269-2813 [Print] England |
PMID | 12182751
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Glucocorticoids
- Mesalamine
- Budesonide
|
Topics |
- Anti-Inflammatory Agents
(therapeutic use)
- Anti-Inflammatory Agents, Non-Steroidal
(therapeutic use)
- Budesonide
(therapeutic use)
- Crohn Disease
(drug therapy)
- Glucocorticoids
(therapeutic use)
- Humans
- Mesalamine
(therapeutic use)
- Randomized Controlled Trials as Topic
- Remission Induction
|